RE:RE:RE:The 2025 PlanYeah !
We expect $1,500,000,000 in revenues in 2025 for Nash only and at least $1 000 000 000 in Oncology ......if the clinical trials show positive results....
realitycheck4u wrote: False. Better to show future potential.
"
SHOW THE MARKET MEANINGFUL INCREASED SALES WITH CURRENT DRUGS AND THE MARKET WILL PAY MORE ATTENTION TO THE PIPELINE" palinc2000 wrote: I think that would be a futile exercise,How about issuing guidance for the next few quarters or better still for the next year,Meeting and exceeding guidance is the best way to prove that you have a good grasp of the operations,The Company was founded in 1993 and issuing guidance has never been in their DNA ,,,SHOW THE MARKET MEANINGFUL INCREASED SALES WITH CURRENT DRUGS AND THE MARKET WILL PAY MORE ATTENTION TO THE PIPELINE
Apart from better operating results the best catalyst would be proof that a major is interested in a collaboration agreement with THTX IN Nash
Wino115 wrote: I'm not sure why they are afraid to discuss the financial THTX implications of the future, with all the risk warnings we would know. Here is an example from another investment I have, Plug Power. Now I fully realize the huge difference between a more predictable industrial roll-out with fewer "binary" events, but that shouldn't stop them from discussing their strategic plan and putting wide bands around it.
Plug Power put in place a 2024 plan with EBITDA and Sales targets and adjusts it as they go along telling you where they are. Here's their investor presentation with the 3rd page being The 2024 Plan with their strategic financial targets. Smart investors know these are just targets, not guarantees and it shows what they are aiming for.
[url=https://https://www.ir.plugpower.com/Home/default.aspx]plug Power IR[/url]